[go: up one dir, main page]

ATE359298T1 - Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen - Google Patents

Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen

Info

Publication number
ATE359298T1
ATE359298T1 AT98929404T AT98929404T ATE359298T1 AT E359298 T1 ATE359298 T1 AT E359298T1 AT 98929404 T AT98929404 T AT 98929404T AT 98929404 T AT98929404 T AT 98929404T AT E359298 T1 ATE359298 T1 AT E359298T1
Authority
AT
Austria
Prior art keywords
tse
laminin receptor
laminin
relates
present
Prior art date
Application number
AT98929404T
Other languages
English (en)
Inventor
Ernst-Ludwig Winnacker
Stefan Weiss
Frank Edenhofer
Roman Rieger
Original Assignee
Stefan Weiss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Weiss filed Critical Stefan Weiss
Application granted granted Critical
Publication of ATE359298T1 publication Critical patent/ATE359298T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/7055Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98929404T 1997-05-30 1998-05-29 Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen ATE359298T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97108712 1997-05-30

Publications (1)

Publication Number Publication Date
ATE359298T1 true ATE359298T1 (de) 2007-05-15

Family

ID=8226854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98929404T ATE359298T1 (de) 1997-05-30 1998-05-29 Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen

Country Status (7)

Country Link
EP (2) EP0984987B1 (de)
JP (1) JP2002501385A (de)
AT (1) ATE359298T1 (de)
AU (1) AU7917598A (de)
CA (1) CA2291720A1 (de)
DE (1) DE69837539T2 (de)
WO (1) WO1998053838A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
DE19918141A1 (de) 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
DE10106076A1 (de) * 2001-02-08 2002-08-22 Susanne Wylezalek Verwendung von Lathyrus Sativus L. zur Herstellung eines Medikamentes zur Behandlung von BSE und BSE-ähnlichen Krankheiten
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
DE10346627A1 (de) 2003-10-08 2005-05-19 Weiss, Stefan, PD Dr. Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
GB201519557D0 (en) * 2015-11-05 2015-12-23 Univ Witwatersrand Jhb Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
GB201700529D0 (en) * 2017-01-12 2017-03-01 Rogers April Laminin receptor peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924984T2 (de) * 1988-05-20 1996-05-23 Jolla Cancer Res Found Adhäsionsrezeptor für laminin und dessen verwendung.
US5180809A (en) * 1988-05-20 1993-01-19 La Jolla Cancer Research Foundation Adhesion receptor for laminin and its use
ATE177754T1 (de) * 1991-12-03 1999-04-15 Proteus Molecular Design Fragmente von prion proteinen.
EP0920630B1 (de) * 1996-05-29 2002-07-31 McGILL UNIVERSITY Prionbindende proteine und deren verwendungen
EP1214943B1 (de) * 1997-12-16 2009-04-01 University Of Zurich T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten

Also Published As

Publication number Publication date
DE69837539T2 (de) 2008-01-03
CA2291720A1 (en) 1998-12-03
DE69837539D1 (de) 2007-05-24
EP0984987B1 (de) 2007-04-11
WO1998053838A3 (en) 1999-05-14
EP1127894A1 (de) 2001-08-29
WO1998053838A2 (en) 1998-12-03
AU7917598A (en) 1998-12-30
EP0984987A2 (de) 2000-03-15
JP2002501385A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
DE60128249D1 (de) Verfahren zur diagnose von immunologischer lebensmittelsensitivität
JP2019535015A5 (de)
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
BRPI0410261B8 (pt) anticorpo monoclonal que se liga especificamente ao probnp, métodos para detecção específica de probnp in vitro e para diagnóstico de insuficiência cardíaca in vitro, kit para medição de probnp, e linhagem celular de hibridoma mab 1.21.3
ATE359298T1 (de) Löslicher laminin rezeptor vorläufer und verfahren zur verhinderung von laminins interaktionen
ATE460430T1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
CA2264939A1 (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
CN106461670A (zh) 糖化蛋白质试验
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
GB2029011A (en) The use of a synthetic bifunctional ligand for the immunometric determination of the concentration ratio of two solutes
CA2235316A1 (en) A method for detecting antipolymer antibodies and a diagnostic test kit for use in aiding the diagnosis of silicone related diseases (srd)
CA2566040A1 (en) Method for increasing the dynamic measuring range of test elements, especially immunological test elements, that are based on specific binding reactions
BR0009843A (pt) Método de diagnosticar encefalopatias esponjiformes transmissìveis
DE69928507D1 (de) Festphasenverfahren und testsatz zur antigen- und antikörperprüfung in der blutgruppen-serologie
DE60318435D1 (de) Universeller biosensor und verfahren zur verwendung
WO2009066787A1 (ja) 血液試料の品質評価方法
Adaszewska et al. The use of BIOCHIP mosaics in diagnostics of bullous pemphigoid: Evaluation and comparison to conventional multistep procedures
DK1090297T3 (da) Fremgangsmåde til påvisning af et antistof i en væskepröve
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
EP0669344A3 (de) Monoklonaler Antikörper und seine Verwendung in einem Immunoassay.
CA2346406A1 (en) Detection of pleiotrophin
JPH08304406A (ja) カリブレーターマトリックス
WO1999047932A3 (en) Diagnosis of spongiform or de-myelinating disease
DE60038557D1 (en) Assay

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties